SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis.
Personalizing JAK inhibitor selection for myelofibrosis by weighing patient factors and new drug combinations may improve outcomes.
Individualized JAK inhibitor selection in myelofibrosis should incorporate dynamic risk scoring, patient comorbidities (anemia, thrombocytopenia), transplant eligibility, and emerging combination data with BET and BCL-2 inhibitors. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Narrative review (SOHO State of the Art series)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Clinical lymphoma, myeloma & leukemia
Why it surfaced
SOHO State of the Art series review on MF treatment selection from MD Anderson experts; covers the full therapeutic landscape including new drugs (momelotinib approval 2023) and combination approaches; essential clinical update for hematologists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.